DDInter993 DDInter1676
Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Isradipine {u} (Compound) resembles {v} (Compound) Amlodipine
Isradipine {u} (Compound) resembles {v} (Compound) Nimodipine
Isradipine {u} (Compound) treats {v} (Disease) hypertension
Isradipine {u} (Compound) binds {v} (Gene) CYP3A4
Isradipine {u} (Compound) upregulates {v} (Gene) KLHL21
Isradipine {u} (Compound) is included by {v} (Pharmacologic Class) Dihydropyridines
Isradipine {u} (Compound) downregulates {v} (Gene) MT2A
Isradipine {u} (Compound) causes {v} (Side Effect) Visual impairment
Isradipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Simvastatin
Isradipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Isradipine (Compound) resembles Amlodipine (Compound)
Isradipine (Compound) resembles Nimodipine (Compound)
Isradipine (Compound) treats hypertension (Disease)
Isradipine (Compound) binds CYP3A4 (Gene)
Isradipine (Compound) upregulates KLHL21 (Gene)
Isradipine (Compound) is included by Dihydropyridines (Pharmacologic Class)
Isradipine (Compound) downregulates MT2A (Gene)
Isradipine (Compound) causes Visual impairment (Side Effect)
Isradipine may cause a minor interaction that can limit clinical effects when taken with Simvastatin
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab